Jarreau Spencer Chen
Pediatric Endocrinology · Madera, CANPI 1205276458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,502, 9.3 times the $161 reported in 2019.
Across 198 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$762
- Novo Nordisk$616
- Kyowa Kirin, Inc.$424
- Neurocrine Biosciences, Inc.$315
- Ascendis Pharma Endocrinology Inc$274
- Xeris Pharmaceuticals, Inc.$228
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $762 |
| Novo Nordisk | 18 | $616 |
| Kyowa Kirin, Inc. | 11 | $424 |
| Neurocrine Biosciences, Inc. | 7 | $315 |
| Ascendis Pharma Endocrinology Inc | 9 | $274 |
| Xeris Pharmaceuticals, Inc. | 11 | $228 |
| Dexcom, Inc. | 8 | $215 |
| Medtronic | 4 | $187 |
| Tolmar, Inc. | 7 | $170 |
| Lilly USA, LLC | 7 | $164 |
| Ultragenyx Pharmaceutical Inc. | 8 | $162 |
| UCB, Inc. | 7 | $160 |
| Sanofi-aventis U.S. LLC | 4 | $152 |
| Rhythm Pharmaceuticals, Inc. | 6 | $151 |
| Pfizer | 5 | $108 |
| Azurity Pharmaceuticals, Inc. | 5 | $98 |
| Tandem Diabetes Care, Inc. | 6 | $97 |
| Abbott | 5 | $96 |
| BETA Bionics, Inc. | 3 | $87 |
| Soleno Therapeutics, Inc. | 2 | $58 |
| Sanofi | 2 | $57 |
| Cequr Corporation | 1 | $55 |
| Biomarin Pharmaceutical Inc. | 2 | $54 |
| Tolmar Pharmaceuticals, Inc. | 2 | $49 |
| Arbor Pharmaceuticals, Inc. | 2 | $39 |
| Mannkind Corporation | 2 | $35 |
| AstraZeneca | 2 | $33 |
| RARE Disease Therapeutics, Inc. | 1 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| QOL Medical, LLC | 1 | $23 |
| Neurelis, Inc. | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Lifescan, Inc. | 1 | $18 |
| Immedica Pharma US, Inc. | 1 | $18 |
| Zogenix Inc. | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Cranial Technologies, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRYSVITA$240
- CRENESSITY$154
- MINIMED 780G$145
- DEXCOM G7 GSS (161)$124
- SKYTROFA$123
- Sogroya$120
- Lupron Depot$106
- TZIELD$106
- Wegovy$105
How this compares
$5,114 in reported general payments places this provider in the 75th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Madera
- Omar AliMadera$5K
- Meenal MendirattaMadera$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Amrit BhangooLong Beach$140K
- Mitchell GeffnerLos Angeles$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.